High-dose transdermal nicotine and naltrexone: Effects on nicotine withdrawal, urges, smoking, and effects of smoking

Experimental and Clinical Psychopharmacology

Volumn 15, Issue 1, 2007, Pages 81-92

  Rohsenow, Damaris J ^a,b,c   Monti, Peter M ^a,b   Hutchison, Kent E ^a,b   Swift, Robert M ^a,b   MacKinnon, Selene V ^a,b   Sirota, Alan D ^a,b   Kaplan, Gary B ^a,b  

^a PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Cue reactivity; Naltrexone; Nicotine replacement; Nicotine withdrawal; Smoking; Smoking abstinence

Indexed keywords

CARBON MONOXIDE; NALTREXONE; NICOTINE; PLACEBO;

ADULT; ARTERIAL PRESSURE; ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPOSURE; FEMALE; HEART RATE VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; BREATH TESTS; CAPSULES; CARBON MONOXIDE; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART RATE; HUMANS; IMPULSE CONTROL DISORDERS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; NICOTINE; NICOTINIC AGONISTS; QUESTIONNAIRES; SMOKING; SUBSTANCE WITHDRAWAL SYNDROME; TABLETS;

EID: 33846992300     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.15.1.81     Document Type: Article

References (54)

1. Balfour, D. J. K. (1994). Neural mechanisms underlying nicotine dependence. Addiction, 89, 1419-1423.
2. Brauer, L. H., Behm, F. M., Westman, E. C., Patel, P., & Rose, J. E. (1999). Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology, 143, 339-346.
3. Cepeda-Benito, A., Reynoso, J. T., & Erath, S. (2004). Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: Differences between men and women. Journal of Consulting and Clinical Psychology, 72, 712-722.
4. Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Erlbaum.
5. Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155-159.
6. Covey, L. S., Glassman, A. G., & Stetner, F. (1999). Naltrexone effects on short-term and long-term smoking cessation. Journal of Addictive Disorders, 18, 31-40.
7. Cox, L. S., Tiffany, S. T., & Christen, A. G. (2001). Evaluation of the Brief Questionnaire of Smoking Urges (QSU-Brief) in laboratory and clinical settings. Nicotine & Tobacco Research, 3, 7-16.
8. Dale, L. C., Hurt, R. D., Offord, K. P., Lawson, G. M., Croghan, I. T., & Schroeder, D. R. (1995). High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. Journal of the American Medical Association, 274, 1353-1358.
9. Del Boca, F. K., Kranzler, H. R., Brown, J., & Korner, P. F. (1996). Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcoholism, Clinical and Experimental Research, 20, 1412-1417.
10. Epstein, A. M., & King, A. C. (2003, February). Naltrexone attenuates behavioral and objective measures of cigarette smoking. Paper presented at the 9th annual meeting of the Society for Research on Nicotine and Tobacco, New Orleans, Louisiana.
11. Garvey, A. J., Bliss, R. E., Hitchcock, J. L., Heinold, J. W., & Rosner, B. (1992). Predictors of smoking relapse among self-quitters: A report from the Normative Aging Study. Addictive Behaviors, 17, 367-377.
12. Gorelick, D. A., Rose, J., & Jarvik, M. E. (1989). Effect of naloxone on cigarette smoking. Journal of Substance Abuse, 1, 153-159.
13. Havermans, R. C., Debaere, S., Smulders, F. T. Y., Wiers, R. W., & Jansen, A. T. M. (2003). Effect of cue exposure, urge to smoke and nicotine deprivation on cognitive performance in smokers. Psychology of Addictive Behaviors, 17, 336-339.
14. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
15. Houtsmuller, E. J., Clemmey, P. A., Sigler, L. A., & Stitzer, M. L. (1997). Effects of naltrexone on smoking and abstinence. In L. S. Harris (Ed.), Problems of drug dependence 1996: Proceedings of the 58th Annual Scientific Meeting (NIDA Research Monograph No. 174, p. 68). Rockville, MD: National Institute of Drug Abuse.
16. Hughes, J. R., Gulliver, S. B., Fenwick, J. W., Cruiser, K., Vallierere, W. A., Pepper, S., et al. (1992). Smoking cessation among self-quitters. Health Psychology, 11, 331-334.
17. Hughes, J. R., & Hatsukami, D. (1986). Signs and symptoms of tobacco withdrawal. Archives of General Psychiatry, 43, 289-294.
18. Hughes, J., & Hatsukami, D. K. (1998). Errors in using tobacco withdrawal scale. Tobacco Control, 7, 92-93.
19. Hughes, J. R., Lesmes, G. R., Hatsukami, D. K., Richmond, R. L., Lichtenstein, E., Jorenby, D. E., et al. (1999). Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine & Tobacco Research, 1, 169-174.
20. Hurt, R. D., Dale, L. C., Offord, K. P., & Croghan, I. T. (1995). Nicotine patch therapy for smoking cessation in recovering alcoholics. Addiction, 90, 1541-1546.
21. Hurt, R. D., Krook, J. E., Croghan, I. T., Loprinzi, C. L., Sloan, J. A., Novotny, P. J., et al. (2003). Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. Journal of Clinical Oncology, 21, 914-920.
22. Hutchison, K. E., Monti, P. M., Rohsenow, D. J., Swift, R., Colby, S. M., Gnys, M., et al. (1999). Effects of naltrexone with nicotine replacement on smoking cue reactivity: Preliminary results. Psychopharmacology, 142, 139-143.
23. Jennings, J. R. (1983). Attention and coronary artery disease. In D. S. Krantz, A. Baum, & J. Singer (Eds.), Advances in behavioral medicine: Cardiovascular disorders (pp. 85-124). Hillsdale, NJ: Erlbaum.
24. Jorenby, D. E., Hatsukami, D. K., Smith, S. S., Fiore, M. C., Allen, S., Jensen, J., & Baker, T. B. (1996). Characterization of tobacco withdrawal symptoms: Transdermal nicotine reduces hunger and weight gain. Psychopharmacology, 128, 130-138.
25. Jorenby, D. E., Smith, S. S., Fiore, M. C., Hurt, R. D., Offord, K. P., Croghan, I. T., et al. (1995). Varying nicotine patch dose and type of smoking cessation counseling. Journal of the American Medical Association, 274, 1347-1352.
26. Kalivas, P. W., & Stewart, J. (1991). Dopamine transmission in the initiation and expression of drug-and stress-induced sensitization of motor activity. Brain Research Review, 16, 223-244.
27. Karras, A., & Kane, J. (1980). Naloxone reduces cigarette smoking. Life Science, 27, 1541-1545.
28. King, A., Chilton, E., Hatsukami, D., & Niaura, R. (2003, February). Efficacy of naltrexone in smoking cessation: Effects of gender on clinical response. Paper presented at the 9th annual meeting of the Society for Research on Nicotine and Tobacco, New Orleans, Louisiana.
29. King, A. C., & Meyer, P. J. (2000). Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacology, Biochemistry, and Behavior, 66, 563-572.
30. Kozlowski, L. T., Mann, R. E., Wilkinson, D. A., & Poulos, C. X. (1989). "Cravings" are ambiguous: Ask about urges or desires. Addictive Behaviors, 14, 443-445.
31. Krishnan-Sarin, S., Meandzija, B., & O'Malley, S. (2003). Naltrexone and nicotine patch in smoking cessation: A preliminary study. Nicotine & Tobacco Research, 5, 851-857.
32. Krishnan-Sarin, S., Rosen, M. I., & O'Malley, S. (1999). Naloxone challenge in smokers: Preliminary evidence of an opioid component in nicotine dependence. Archives of General Psychiatry, 56, 663-668.
33. Levin, E. D., Westman, E. C., Stein, R. M., Carnahan, E., Sanchez, M., Herman, S., et al. (1994). Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. Journal of Clinical Psychopharmacology, 14, 41-49.
34. Mason, B. J. (2005, June). Naltrexone and Nicotrol for concurrent tobacco and alcohol dependence. In Rohsenow, D. J., & Fertig, J. (Chairs), Smoking and alcohol abuse: From lab to clinic. Satellite symposium conducted at the annual meeting of the Research Society on Alcoholism, Santa Barbara, CA.
35. Mason, B. J., Williams, L. D., Salvato, F. R., Mestre, S., & Culter, R. B. (2004). Naltrexone treatment for concurrent tobacco and alcohol dependence. Alcoholism, Clinical and Experimental Research, 28, 114A.
36. Nemeth-Coslett, R., & Griffiths, R. R. (1986). Naloxone does not affect cigarette smoking. Psychopharmacology, 89, 261-264.
37. Niaura, R. S., Hitsman, B., Abrams, D. B., Rohsenow, D. J., & Monti, P. M. (2003). Validation and replication of the Nicotine Effects Questionnaire. Nicotine & Tobacco Research, 5, 788.
38. Perkins, K. A., Gerlach, D., Wilson, A., Broge, M., & Fonte, C. (2001). Reinforcing effects of nicotine as a function of smoking status. Experimental and Clinical Psychopharmacology, 9, 243-250.
39. Pickens, R. W., & Johanson, C. E. (1992). Craving: Consensus of status and agenda for future research. Drug and Alcohol Dependence, 30, 127-131.
40. Robinson, T. E., & Berridge, K. C. (1993). The neural basis of drug craving: An incentive-sensitization theory of addiction. Brain Research Review, 18, 247-291.
41. Rohsenow, D. J. (1982). Control over interpersonal evaluation and alcohol consumption in male social drinkers. Addictive Behaviors, 7, 113-121.
42. Rohsenow, D. J., Monti, P. M., Colby, S. M., Gulliver, S. B., Swift, R. M., & Abrams, D. B. (2003). Naltrexone treatment for alcoholics: Effect on cigarette smoking rates. Nicotine & Tobacco Research, 5, 231-236.
43. Rohsenow, D. J., & Niaura, R. S. (1999). Comments on "Meta-analysis of cue reactivity in addiction research": Reflections on the state of cue reactivity theories and research. Addiction, 94, 343-344.
44. Sayette, M. A., & Hufford, M. R. (1994). Effects of cue exposure and deprivation on cognitive resources in smokers. Journal of Abnormal Psychology, 103, 812-818.
45. Shiffman, S. (1982). Relapse following smoking cessation: A situational analysis. Journal of Consulting and Clinical Psychology, 50, 71-86.
46. Shiffman, S., Sweeney, C. T., & Dresler, C. M. (2005). Nicotine patch and lozenge are effective for women. Nicotine & Tobacco Research, 7, 119-127.
47. Sutherland, G., Stapleton, J. A., Russell, M. A. H., & Feyerband, G. (1995). Naltrexone, smoking behavior and cigarette withdrawal. Psychopharmacology, 120, 418-425.
48. Teneggi, V., Tiffany, S. T., Squassante, L., Milleri, S., Ziviani, L., & Bye, A. (2002). Smokers deprived of cigarettes for 72 hours: Effect of nicotine patches on craving and withdrawal. Psychopharmacology, 164, 177-187.
49. Tidey, J. W., Rohsenow, D. J., Kaplan, G. K., & Swift, R. M. (2005). Subjective and physiological responses to smoking cues in smokers with schizophrenia. Nicotine & Tobacco Research, 7, 421-429.
50. Tiffany, S. T., Cox, L. S., & Elash, C. A. (2000). Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. Journal of Consulting and Clinical Psychology, 68, 233-240.
51. U.S. Department of Health and Human Services. (2000). Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service.
52. Wise, R. A. (1988). The neurobiology of craving: Implications for the understanding and treatment of addiction. Journal of Abnormal Psychology, 97, 118-132.
53. Wong, G. Y., Wolter, T. D., Croghan, G. A., Croghan, I. T., Offord, K. P., & Hurt, R. D. (1999). A randomized trial of naltrexone for smoking cessation. Addiction, 94, 1227-1237.
54. Yudkin, P., Munafo, M., Hey, K., Roberts, S., Welch, S., Johnstone, E., et al. (2004). Effectiveness of nicotine patches in relation to genotype in women versus men: Randomized controlled trial. British Medical Journal, 328, 989-990.